- Case report
- Open Access
- Open Peer Review
Treatment of cardiogenic shock with left ventricular assist device combined with cardiac resynchronization therapy: A case report
© Keilegavlen et al; licensee BioMed Central Ltd. 2010
- Received: 25 January 2010
- Accepted: 2 July 2010
- Published: 2 July 2010
Cardiogenic shock has a poor prognosis with established treatment strategies. We report a 62 years old man with heart failure exacerbating into refractory cardiogenic shock successfully treated with the combination of a percutaneous left ventricular assist device (LVAD) and subacute cardiac resynchronization therapy (CRT) implantable cardioverter-defibrillator device (CRT-D).
- Leave Ventricular Ejection Fraction
- Cardiac Resynchronization Therapy
- Cardiogenic Shock
- Left Ventricular Assist Device
- Left Bundle Branch Block
The mortality rate in patients with cardiogenic shock is still very high . Medical therapy has symptomatic effects, but has no proven reduction of mortality. Percutaneously placed LVAD is an option for selected groups of these patients. The percutaneous microaxial blood pump, Impella LP 2.5® (Abiomed; Aachen, Germany) can be rapidly deployed with low complication rates and have improved hemodynamic effects compared with the intraaortic balloon pump (IABP) [2–4]. Furthermore, in selected patients with stable heart failure, CRT is proven to relive symptoms and improve outcomes . The potential efficiency of acute and subacute CRT treatment in patients with cardiogenic shock has to our knowledge not been studied.
A previously healthy 62 years old man who had experienced reduced exercise capacity for the last 6 months was admitted to the local hospital after 2 weeks of increasing dyspnoea. Echocardiography revealed biventricular dilatation, reduced wall thickness, asynchronous left ventricular (LV) contraction and left ventricular ejection fraction (LVEF) of 10%. ECG showed left bundle branch block (QRS width 170 msec). The clinical condition deteriorated rapidly into a cardiogenic shock. Multiorgan failure developed including hepatic dysfunction and renal impairment. The following day, he was transferred to our hospital for LVAD therapy. An Impella LP 2.5® was percutaneously deployed, and the mean arterial pressure immediately improved from 50 mmHg to 70 mmHg and the vasopressor drugs could be stopped. Coronary angiography showed normal coronary arteries. The patient clinically improved and INR and s-creatinine normalized during the first three days.
In the reported case, the patient presented with untreated severe decompensated dilated cardiomyopathy with hemodynamic instability exacerbating into cardiogenic shock refractory to standard intensive medical treatment. IABP has been the most widely used mechanical hemodynamic assist device. In spite of beneficial hemodynamic effects and a low complication rate, no randomized clinical studies have shown reduction of mortality . Other available hemodynamic support strategies include surgical cardiopulmonary support (CPS) and different percutaneous LVAD systems (i.e. the TandemHeart® and the Impella LP 2.5/5.0®). The Impella LP 2.5® is inserted via the femoral artery and advanced retrogradly into the left ventricle. An electromagnetic motor draws blood from the inflow port in the left ventricle to the outflow port in the proximal ascending aorta close to the inlet of the coronary arteries. Small studies comparing IABP and Impella in cardiogenic shock may indicate beneficial hemodynamic effects of the percutaneous LVAD [3, 4]. Experimental studies have shown that Impella LP 2.5® may sustain vital organ perfusion even during cardiac arrest . Thus, the percutaneous LVAD may have potential to significantly improve hemodynamics in selected critically ill patients.
CRT improves symptoms and reduces mortality by 36% in patients with ischemic and non-ischemic cardiomyopathy in NYHA class III-IV. This is documented for stable patients on optimal medical therapy with dilated LV, LVEF ≤ 35% and QRS width > 120 ms . The benefit of CRT in cardiogenic shock has not been studied. Some observational studies have reported beneficial outcome from CRT in inotrope-supported patients with end-stage heart failure [7, 8], and there are case reports on clinical improvement effected by CRT in patients on IABP support . The rapid onset of hemodynamic improvement of CRT may be of clinical benefit in an acute setting and it is likely that CRT has an additive effect on the unloading of the left ventricle and improved organ perfusion achieved by the LVAD in patient with cardiogenic shock. This should be judged against the elevated risk of complications using mechanical devices in this group of unstable patients. The use of LVAD and CRT combined in cardiogenic shock has to our knowledge not been reported previously.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
- Jeger RV, Radovanovic D, Hunziker PR, Pfisterer ME, Stauffer JC, Erne P, Urban P: Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med. 2008, 149: 618-26.View ArticlePubMedGoogle Scholar
- Sjauw KD, Engström AE, Vis MM: A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines?. Eur Heart J. 2009, 30: 459-68. 10.1093/eurheartj/ehn602.View ArticlePubMedGoogle Scholar
- Seyfarth M, Sibbing D, Bauer I, Fröhlich G, Bott-Flügel L, Byrne R, Dirschinger J, Kastrati A, Schömig A: A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008, 52: 1584-8. 10.1016/j.jacc.2008.05.065.View ArticlePubMedGoogle Scholar
- Thiele H, Sick P, Boudriot E, Diederich KW, Hambrecht R, Niebauer J, Schuler G: Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2005, 26: 1276-83. 10.1093/eurheartj/ehi161.View ArticlePubMedGoogle Scholar
- Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L: The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005, 352: 1539-49. 10.1056/NEJMoa050496.View ArticlePubMedGoogle Scholar
- Tuseth V, Salem M, Pettersen R, Grong K, Rotevatn S, Wentzel-Larsen T, Nordrehaug JE: Percutaneous left ventricular assist in ischemic cardiac arrest. Crit Care Med. 2009, 37: 1365-72. 10.1097/CCM.0b013e31819c0642.View ArticlePubMedGoogle Scholar
- Herweg B, Ilercil A, Cutro R, Dewhurst R, Krishnan S, Weston M, Barold SS: Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure. Am J Cardiol. 2007, 100: 90-3. 10.1016/j.amjcard.2007.02.058.View ArticlePubMedGoogle Scholar
- Cowburn PJ, Patel H, Jolliffe RE, Wald RW, Parker JD: Cardiac resynchronization therapy: an option for inotrope-supported patients with end-stage heart failure?. Eur J Heart Fail. 2005, 7: 215-7. 10.1016/j.ejheart.2004.11.005.View ArticlePubMedGoogle Scholar
- Rao BH, Kalavakolanu S, Chandrasekar K, Sastry BK, Narasimhan C: Cardiac Resynchronization Therapy in Hemodynamically Unstable Heart Failure Patients. Indian Heart J. 2007, 59: 185-7.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.